Table 1.

Baseline characteristics and clinical presentations of study participants.

	IV group (n = 146)	PO group (n = 98)	p value
Age, years, mean ± SD	54 ± 16.3	53 ± 15.5	0.53
Male, n (%)	95 (65.1)	66 (66.3)	0.78
Ethnicity/race, n (%)			0.54
White	14 (9.6)	6 (6.1)
African American	12 (8.2)	7 (7.1)
Hispanic	89 (61.0)	68 (69.4)
Asian	8 (5.5)	2 (2.0)
Unknown	23 (15.8)	15 (15.3)
Residence prior to admission, n (%)			0.44
Home	112 (76.7)	72 (73.5)
LTCF/SNF	3 (2.1)	1 (1.0)
Community housing/Shelter	2 (1.4)	4 (4.1)
Homeless	21 (14.4)	13 (13.4)
Jail	8 (5.5)	6 (6.1)
Outside hospital	0 (0.0)	2 (2.0)
Prior hospitalization, n (%)	39 (26.7)	18 (18.4)	0.16
IV drug use history, n (%)	13 (8.9)	2 (2.0)	0.03
Immunocompromised, n (%)	31 (21.2)	22 (22.4)	0.87
Chemotherapy w/n 6 mo	12 (8.2)	7 (7.1)	0.81
Absolute neutrophil count ⩽ 100	0 (0.0)	0 (0.0)	>0.99
Immunomodulatory therapy or corticosteroids ⩾ 14 days	10 (6.8)	5 (5.1)	0.79
Other comorbidities, n (%)
End-stage renal disease	7 (4.8)	2 (2.0)	0.32
Liver dysfunction	27 (18.5)	19 (19.4)	0.87
Diabetes mellitus	45 (30.8)	26 (26.5)	0.57
Congestive heart failure	7 (4.8)	6 (6.1)	0.77
CCI, median (IQR)	3 (1–5)	2 (1–5)	0.07
Co-infections, n (%)	31 (21.2)	10 (10.2)	0.04
ICU admission, n (%)	61 (41.8)	38 (38.8)	0.69
Use of vasopressor and mechanical ventilation, n (%)
Use of vasopressor	10 (6.8)	5 (5.1)	0.68
Mechanical ventilation	8 (5.5)	5 (5.1)	0.98
Both	7 (4.8)	2 (2.0)	0.48
Lactate, median (IQR)	2.0 (1.4–2.95)	1.7 (1.3–3.2)	0.66
Pitt bacteremia score
0–1	105 (71.9)	73 (75.5)	0.69
2–3	41 (28.1)	25 (25.5)
Median (IQR)	1 (0–2)	0 (0–2)	0.97

CCI, Charlson Comorbidity Index; ICU, intensive care unit; IQR, interquartile range; IV, intravenous; LTCF, long-term care facility; PO, oral; SD, standard deviation; SNF, skilled nursing facility.